The Oncology Institute, Inc. (DFPH) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Talkspace, Inc.

Nutex Health, Inc.

Precipio, Inc.

Aveanna Healthcare Holdings, Inc.

The Pennant Group, Inc.

LifeMD, Inc.

The Joint Corp. (United States)

The Oncology Institute, Inc.

Biodesix, Inc.

CareMax, Inc.

Invitae Corp.

Why is The Oncology Institute, Inc. ?

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate -308.74% of over the last 5 years
Low ability to service debt as the company has a high Debt to EBITDA ratio of -1.00 times

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 152.42%, its profits have risen by 30.1%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is The Oncology Institute, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

The Oncology Institute, Inc.

151.61%

6.08

98.01%

S&P 500

13.68%

0.71

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

241.14%

EBIT Growth (5y)

-308.74%

EBIT to Interest (avg)

-18.48

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

8.08

Sales to Capital Employed (avg)

3.53

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

50.07%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-27.46

EV to EBIT

-9.55

EV to EBITDA

-11.52

EV to Capital Employed

9.04

EV to Sales

0.85

PEG Ratio

Dividend Yield

ROCE (Latest)

-94.66%

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

19What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -23.63 MM

NET SALES(Q)

Highest at USD 136.56 MM

RAW MATERIAL COST(Y)

Fallen by 1.86% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -618.32 %

DEBTORS TURNOVER RATIO(HY)

Highest at 8.03 times

OPERATING PROFIT(Q)

Highest at USD -6.33 MM

OPERATING PROFIT MARGIN(Q)

Highest at -4.64 %

PRE-TAX PROFIT(Q)

Highest at USD -10.38 MM

NET PROFIT(Q)

Highest at USD -7.64 MM

EPS(Q)

Highest at USD -0.14

-5What is not working for the Company

INTEREST(9M)

At USD 9.36 MM has Grown at 47.91%

ROCE(HY)

Lowest at -3,407.86%

Here's what is working for The Oncology Institute, Inc.

Operating Cash Flow

Highest at USD -23.63 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales

Highest at USD 136.56 MM and Grown

In each period in the last five periods

MOJO Watch

Near term sales trend is very positive

Net Sales (USD MM)

Net Sales

At USD 136.56 MM has Grown at 36.7%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Operating Profit

Highest at USD -6.33 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin

Highest at -4.64 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at USD -10.38 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD -7.64 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD -0.14

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Debt-Equity Ratio

Lowest at -618.32 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio

Highest at 8.03 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by 1.86% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for The Oncology Institute, Inc.

Interest

At USD 9.36 MM has Grown at 47.91%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)